Related Topics



Genea Gets Orphan Drug Designation

Genea Biocells Announces FDA Orphan Drug Designation for GBC0905 For The Treatment Of  Facioscapulohumeral Muscular Dystrophy (FSHD) San Diego (CA), May 30, 2018 -- Genea Biocells, a preclinical-stage company focused on...

Read More

Genea Biocells partners with AMSBIO

Genea Biocells (San Diego, USA) has partnered with AMSBIO for global distribution to the academic community for its leading-edge skeletal muscle differentiation kits.   For more information please visit:  AMSBIO and Genea Biocells...

Read More

Stem Cells Bring Hope for Dystrophies

Genea Biocells, a world leader in skeletal muscle differentiation also possesses one of the world’s largest and most varied private human embryonic stem cell banks–giving us the ability to recapitulate...

Read More